Dr Alan Richardson

Title: Senior Lecturer in Pharmacology
Phone: 01782 733571 (Teaching) or 01728 555227 (Research)
Email: a.richardson1@keele.ac.uk
Location: Hornbeam Building, Room 1.08
Role: Pharmacology Lead
Contacting me: E-mail
Alan Richardson

I joined the School of Pharmacy in 2008. Following a PhD and post-doctoral work in pharmacology at Cambridge, I completed my post-doctoral training at the University of Virginia, USA. Following several years leading drug discovery programs in industry (Johnson & Johnson, Belgium and OSI pharmaceuticals, Oxford) I returned to academic research at the Institute of Cancer Research in London. At Keele, I lead teaching of pharmacology including option topics focusing on oncology molecular therapeutics. I also make teaching contributions to the School of Life Sciences and the School of Medicine. I am currently third year tutor. My research interests focus on discovering new therapeutic targets and drugs for the treatment of ovarian cancer. I have received funding from charities and research councils.

Research

Education

  • Together with Luke Bracegirdle, I have developed "KUiz" a tool to allow academic staff to create rapidly a quiz for students that can be viewed on a smartphone or PC. For details please visit http://www.kuiz.co.uk/
  • I use the Keele KAVE to teach molecular pharmacology in a 3D virtual environment, and I have shown that this improves student learning (in press, American Journal of Pharmacy Education).
  • I have led the development of a synoptic assessment that allows students to integrate and entire year's learning (manuscript in preparation).
  • I have developed an inexpensive method for simulating drug-receptor interactions in a classroom (manuscript submitted for publication).

Selected Publications

  • Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis ADM, Richardson A. 2013. Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol, vol. 129(2), 417-424. link> doi>
  • Stamelos VA, Robinson E, Redman CW, Richardson A. 2013. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells. Gynecol Oncol, vol. 128(2), 377-382. link> doi>
  • Richardson A, Underwood JK, Allin SM, Redman CW. 2012. Autotaxin - a target for the treatment of drug-resistant ovarian cancer?. In Ovarian cancer - basic science perspective. Farghaly S (Ed.). (vol. 1). Intech. link>
  • Stamelos VA, Redman CW, Richardson A. 2012. Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. J Mol Signal, vol. 7(1), 12. link> doi>
  • Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, Kaye SB, Richardson A. 2010. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. CELLULAR SIGNALLING, vol. 22(6), 926-935. link> doi>

Full Publications List show

Journal Articles

  • Abdullah MI, Abed MN, Richardson A. 2017. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells. Sci Rep, vol. 7(1), 8090. link> doi>
  • de Wolf E, Abdullah MI, Jones SM, Menezes K, Moss DM, Drijfhout FP, Hart SR, Hoskins C, Stronach EA, Richardson A. 2017. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Sci Rep, vol. 7(1), 5410. link> doi>
  • Robinson E, Jones S, Menezes K, Abdullah M, Stronach E, Hoskins C, Richardson A. 2016. Pitavastatin is a potential treatment for drug-resistant ovarian cancer. European Journal of Cancer, vol. 61(1), 192. doi> link>
  • Uche FI, Drijfhout FP, McCullagh J, Richardson A, Li W-W. 2016. Cytotoxicity Effects and Apoptosis Induction by Bisbenzylisoquinoline Alkaloids from Triclisia subcordata. Phytother Res, vol. 30(9), 1533-1539. link> doi>
  • Abed MN, Abdullah MI, Richardson A. 2016. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res, vol. 9, 25. link> doi>
  • Stamelos VA, Fisher N, Bamrah H, Voisey C, Price JC, Farrell WE, Redman CW, Richardson A. 2016. The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization. PloS one, vol. 11(3), e0150696. doi>
  • Kitchen MO, Yacqub-Usman K, Emes RD, Richardson A, Clayton RN, Farrell WE. 2015. Epidrug mediated re-expression of miRNA targeting the HMGA transcripts in pituitary cells. Pituitary, vol. 18(5), 674-684. link> doi>
  • Johnson-Ajinwo OR, Richardson A, Li W-W. 2015. Cytotoxic effects of stem bark extracts and pure compounds from Margaritaria discoidea on human ovarian cancer cell lines. Phytomedicine, vol. 22(1), 1-4. link> doi>
  • Richardson A, Curtis ADM, Moss GP, Pearson RJ, White S, Rutten FJM, Perumal D, Maddock K. 2014. Simulated drug discovery process to conduct a synoptic assessment of pharmacy students. Am J Pharm Educ, vol. 78(2), 41. link> doi>
  • Robinson E, Fisher N, Stamelos V, Redman C, Richardson A. 2014. New strategies for the treatment of ovarian cancer. Biochem Soc Trans, vol. 42(1), 125-129. link> doi>
  • Fisher N, Hilton-Bolt T, Edwards MG, Haxton KJ, McKenzie M, Allin SM, Richardson A. 2014. Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor. ACS Med Chem Lett, vol. 5(1), 34-39. link> doi>
  • Jain HV, Richardson A, Meyer-Hermann M, Byrne HM. 2014. Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas. PLoS One, vol. 9(1), e81582. link> doi>
  • Fisher N, Edwards M, Allin S, Richardson A. 2013. AUTOTAXIN INHIBITORS AS A POTENTIAL TREATMENT FOR OVARIAN. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 23(8). link>
  • Richardson A and Robinson E. 2013. THE POTENTIAL FOR STATINS IN THE TREATMENT OF OVARIAN CANCER. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 23(8). link>
  • Maddock K. 2013. Chairs, bells and students – a novel method to simulate and teach molecular interactions in pharmacology. Pharmacy Education, vol. 13, 36-39. link>
  • Robinson E, Nandi M, Wilkinson L, Arrowsmith M, Curtis ADM, Richardson A. 2013. Preclinical Evaluation of Statins as a Treatment for Ovarian Cancer. Gynecologic Oncology, vol. 129, 417-424. doi>
  • Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis ADM, Richardson A. 2013. Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol, vol. 129(2), 417-424. link> doi>
  • Richarson A, Bracegirdle L, McLachlan SIH, Chapman SR. 2013. Use of a Three-Dimensional Virtual Environment to Teach Drug-Receptor Interactions. American Journal of Pharmaceutical Education, vol. 77(1), Article 11. doi> link>
  • Richardson A and Robinson E. 2013. The potential for statins in the treatment of ovarian cancer. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 32, S67. link>
  • Stamelos VA, Robinson E, Redman CW, Richardson A. 2013. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells. Gynecol Oncol, vol. 128(2), 377-382. link> doi>
  • Yacqub-Usman K, Richardson A, Duong CV, Clayton RN, Farrell WE. 2012. The pituitary tumour epigenome: aberrations and prospects for targeted therapy. Nat Rev Endocrinol, vol. 8(8), 486-494. link> doi>
  • Stamelos VA, Redman CW, Richardson A. 2012. Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. J Mol Signal, vol. 7(1), 12. link> doi>
  • Al-Azzawi H, Yacqub-Usman K, Richardson A, Hofland LJ, Clayton RN, Farrell WE. 2011. Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis. Endocrinology, vol. 152(2), 364-373. link> doi>
  • Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, Kaye SB, Richardson A. 2010. Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. CELLULAR SIGNALLING, vol. 22(6), 926-935. link> doi>
  • Rowther FB, Richardson A, Clayton RN, Farrell WE. 2010. Bromocriptine and dopamine mediate independent and synergistic apoptotic pathways in pituitary cells. Neuroendocrinology, vol. 91(3), 256-267. link> doi>
  • Richardson A and Kaye SB. 2008. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol, vol. 1(3), 244-254. link> doi>
  • Witham J, Vidot S, Kaye SB, Richardson A. 2008. Transient ectopic expression as a method to detect genes conferring drug resistance. International Journal of Cancer, vol. 122, 2641-2645. doi>
  • Witham J, Valenti M, De-Haven Brandon A, Vidot S, Eccles S, Kaye S, Richardson A. 2007. The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin. Clinical Cancer Research, vol. 13, 7198. doi>
  • Mortier E, Cornelissen F, van Hove C, Dillen L, Richardson A. 2001. The focal adhesion targeting sequence is the major inhibitory moiety of Fak-related non-kinase. CELLULAR SIGNALLING, vol. 13(12), 901-909. link> doi>
  • Ma A, Richardson A, Schaefer EM, Parsons JT. 2001. Serine phosphorylation of focal adhesion kinase in interphase and mitosis: A possible role in modulating binding to p130(Cas). MOLECULAR BIOLOGY OF THE CELL, vol. 12(1), 1-12. link> doi>
  • Masure S, Haefner B, Wesselink JJ, Hoefnagel E, Mortier E, Verhasselt P, Tuytelaars A, Gordon R, Richardson A. 1999. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 265(1), 353-360. link> doi>
  • Taylor JM, Richardson A, Parsons JT. 1998. Modular domains of focal adhesion-associated proteins. PROTEIN MODULES IN SIGNAL TRANSDUCTION, vol. 228, 135-163. link>
  • Richardson A, Malik RK, Hildebrand JD, Parsons JT. 1997. Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: A role for paxillin tyrosine phosphorylation. MOLECULAR AND CELLULAR BIOLOGY, vol. 17(12), 6906-6914. link> doi>
  • Richardson A, Shannon JD, Adams RB, Schaller MD, Parsons T. 1997. Identification of integrin-stimulated sites of serine phosphorylation in FRNK, the separately expressed C-terminal domain of focal adhesion kinase: A potential role for protein kinase A. BIOCHEMICAL JOURNAL, vol. 324, 141-149. link> doi>
  • Burnham MR, Harte MT, Richardson A, Parsons JT, Bouton AH. 1996. The identification of p130(cas)-binding proteins and their role in cellular transformation. ONCOGENE, vol. 12(11), 2467-2472. link>
  • Richardson A and Parsons JT. 1996. A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125(FAK). NATURE, vol. 380(6574), 538-540. link> doi>
  • Parsons JT, Richardson A, Hildebrand J, Harte M, Bouton A. 1996. Focal adhesion-associated kinases and cell signalling. JOURNAL OF NEUROCHEMISTRY, vol. 66, S7. link>
  • RICHARDSON A and PARSONS JT. 1995. SIGNAL-TRANSDUCTION THROUGH INTEGRINS - A CENTRAL ROLE FOR FOCAL ADHESION KINASE. BIOESSAYS, vol. 17(3), 229-236. link> doi>
  • RICHARDSON A and TAYLOR CW. 1993. EFFECTS OF CA2+ CHELATORS ON PURIFIED INOSITOL 1,4,5-TRISPHOSPHATE (INSP3) RECEPTORS AND INSP3-STIMULATED CA2+ MOBILIZATION. JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268(16), 11528-11533. link>
  • OLDERSHAW KA, RICHARDSON A, TAYLOR CW. 1992. PROLONGED EXPOSURE TO INOSITOL 1,4,5-TRISPHOSPHATE DOES NOT CAUSE INTRINSIC DESENSITIZATION OF THE INTRACELLULAR CA2+-MOBILIZING RECEPTOR. JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267(23), 16312-16316. link>
  • RICHARDSON A, SIMON J, BARNARD EA. 1992. PROTECTION BY OPIOID LIGANDS AGAINST MODIFICATION OF THE OPIOID RECEPTOR BY A CARBODIIMIDE. BIOCHEMICAL PHARMACOLOGY, vol. 43(7), 1415-1419. link> doi>
  • TAYLOR CW and RICHARDSON A. 1991. STRUCTURE AND FUNCTION OF INOSITOL TRISPHOSPHATE RECEPTORS. PHARMACOLOGY & THERAPEUTICS, vol. 51(1), 97-137. link> doi>
  • Li WW, Rosa JO, Siddique MR, Bajana B, Sule-Suso J, Richardson A. 2013. Anti-cancer thymoquinone from Nigella sativa. PLANTA MEDICA, vol. 79(13), 1126. link>
  • PARSONS JT, SCHALLER MD, HILDEBRAND J, LEU TH, RICHARDSON A, OTEY C. 1994. FOCAL ADHESION KINASE - STRUCTURE AND SIGNALING. JOURNAL OF CELL SCIENCE, 109-113. link>
  • Richardson A, Demoliou-Mason C, Barnard EA. Guanine nucleotide-binding protein-coupled and -uncoupled states of opioid receptors and their relevance to the determination of subtypes. Proceedings of the National Academy of Sciences of USA, vol. 89(21), 10198-10202. link>
  • Richardson A and Taylor C. 1992. Purification of the inositol1,4,5-trisphosphate receptor by heparin affinity chromatography using decavandate. Biochem Soc Trans, vol. 20(2), 135S. link> doi>
  • Robinson E, Leung E, Matuszek AM, Krogsgaard-Larsen N, Furkert DP, Brimble MA, Richardson A, Reynisson J. 2015. Virtual screening for novel Atg5-Atg16 complex inhibitors for autophagy modulation. MEDCHEMCOMM, vol. 6(1), 239-246. link> doi>

Chapters

  • Richardson A, Underwood JK, Allin SM, Redman CW. 2012. Autotaxin - a target for the treatment of drug-resistant ovarian cancer?. In Ovarian cancer - basic science perspective. Farghaly S (Ed.). (vol. 1). Intech. link>

Other

  • Johnson-Ajinwo OR, Richardson A, Li W-W. 2017. Identification and evaluation of anticancer compounds from three Nigerian plants used in traditional medicines. BIOCHEMICAL PHARMACOLOGY (vol. 139, p. 128). link> doi>
  • Uche FI, Abed M, Abdullah MI, Drijfhout FP, McCullagh J, Claridge TWD, Richardson A, Li W-W. 2017. Isolation, identification and anti-cancer activity of minor alkaloids from Triclisia subcordata Oliv. BIOCHEMICAL PHARMACOLOGY (vol. 139, p. 112). link> doi>
  • Uche F, Abed M, Abdullah M, Drijfhout FP, McCullagh J, Claridge T, Richardson A, Li WW. 2017. O9 Isolation, identification and anti-cancer activity of minor alkaloids from Triclisia subcordata Oliv. Biochemical Pharmacology (vol. 139). Elsevier BV. doi> link>
  • Johnson-Ajinwo OR, Richardson A, Li WW. 2017. P11 Identification and evaluation of anticancer compounds from three Nigerian plants used in traditional medicines. Biochemical Pharmacology (vol. 139, p. 128). Elsevier BV. doi> link>
  • Abed MN and Richardson A. 2016. Inhibition of BCKDK increases the sensitivity of ovarian cancer cells to paclitaxel. EUROPEAN JOURNAL OF CANCER (vol. 69, p. S20). link> doi>
  • Robinson E, Abdullah M, Jones S, Menezes K, Euan S, Hoskins C, Richardson A. 2016. Preclinical evaluation of pitavastatin as a treatment for chemotherapy-resistant ovarian cancer. EUROPEAN JOURNAL OF CANCER (vol. 69, p. S150). link> doi>
  • Uche FI, Li WW, Richardson A, Greenhough TJ. 2014. Anticancer activities of cyclotides from Viola yedeonsis Makino (Violaceae). PLANTA MEDICA (vol. 80, p. 818). link>
  • Uche F, Li WW, Richardson A, Greenhough TJ. 2014. Anti-ovarian cancer activities of alkaloids from Triclisia subcordata olive (Menispermecaea). PLANTA MEDICA (vol. 80, p. 813). link>
  • Richardson M, Robinson E, Turner C, Allin S, Richardson A, Pearson R. 2012. Novel heterocyclic NO-donors as potential anti-cancer agents. NITRIC OXIDE-BIOLOGY AND CHEMISTRY (vol. 27, p. S37). link> doi>
  • Richardson A. 3- phenyl analogs of toxoflavine as kinase inhibitors.
  • Richardson A. 3-furanyl analogs of toxoflavine as kinase inhibitors.
  • Richardson A. Human Akt-3.